| Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity C Fougeroux, L Goksøyr, M Idorn, V Soroka, SK Myeni, R Dagil, ... Nature Communications 12 (1), 324, 2021 | 96 | 2021 |
| Site-specific O-glycosylation analysis of SARS-CoV-2 spike protein produced in insect and human cells I Bagdonaite, AJ Thompson, X Wang, M Søgaard, C Fougeroux, M Frank, ... Viruses 13 (4), 551, 2021 | 68 | 2021 |
| Future prospects for the development of cost-effective adenovirus vaccines C Fougeroux, PJ Holst International journal of molecular sciences 18 (4), 686, 2017 | 56 | 2017 |
| Quality control of microbiota metagenomics by k-mer analysis F Plaza Onate, JM Batto, C Juste, J Fadlallah, C Fougeroux, D Gouas, ... BMC genomics 16, 1-10, 2015 | 34 | 2015 |
| Two-component nanoparticle vaccine displaying glycosylated spike S1 domain induces neutralizing antibody response against SARS-CoV-2 variants L van Oosten, JJ Altenburg, C Fougeroux, C Geertsema, F van den End, ... MBio 12 (5), 10.1128/mbio. 01813-21, 2021 | 30 | 2021 |
| Identification and characterization of serovar-independent immunogens in Actinobacillus pleuropneumoniae F Antenucci, C Fougeroux, JT Bossé, Z Magnowska, C Roesch, ... Veterinary research 48, 1-12, 2017 | 26 | 2017 |
| In vivo testing of novel vaccine prototypes against Actinobacillus pleuropneumoniae F Antenucci, C Fougeroux, A Deeney, C Ørskov, A Rycroft, PJ Holst, ... Veterinary research 49, 1-11, 2018 | 25 | 2018 |
| First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2 MJ Smit, AF Sander, MBPA Ariaans, C Fougeroux, C Heinzel, R Fendel, ... The Lancet Microbe 4 (3), e140-e148, 2023 | 15 | 2023 |
| The potential of adenoviral vaccine vectors with altered antigen presentation capabilities L Neukirch, C Fougeroux, AMC Andersson, PJ Holst Expert review of vaccines 19 (1), 25-41, 2020 | 15 | 2020 |
| Modified MHC Class II–Associated Invariant Chain Induces Increased Antibody Responses Against Plasmodium Falciparum Antigens After Adenoviral Vaccination C Fougeroux, L Turner, AM Bojesen, T Lavstsen, PJ Holst The Journal of Immunology 202 (8), 2320-2331, 2019 | 15 | 2019 |
| An S1-nanoparticle vaccine protects against SARS-CoV-2 challenge in K18-hACE2 mice L van Oosten, K Yan, DJ Rawle, TT Le, JJ Altenburg, C Fougeroux, ... Journal of Virology 96 (14), e00844-22, 2022 | 7 | 2022 |
| Capsid-like particles decorated with the SARS-CoV-2 receptorbinding domain elicit strong virus neutralization activity. Nat Commun 12: 324 C Fougeroux, L Goksøyr, M Idorn, V Soroka, SK Myeni, R Dagil, ... | 7 | 2021 |
| Replication deficient human adenovirus vector serotype 19a/64: Immunogenicity in mice and female cynomolgus macaques E Ragonnaud, S Schroedel, S Mariya, D Iskandriati, J Pamungkas, ... Vaccine 36 (41), 6212-6222, 2018 | 6 | 2018 |
| SARS-CoV-2 RBD-specific antibodies induced early in the pandemic by natural infection and vaccination display cross-variant binding and inhibition MR Walker, D Podlekareva, S Johnsen, B Leerhøy, C Fougeroux, ... Viruses 14 (9), 1861, 2022 | 4 | 2022 |
| Development of a Tag/Catcher-mediated capsid virus-like particle vaccine presenting the conserved Neisseria gonorrhoeae SliC antigen that blocks human lysozyme FG Martinez, RA Zielke, CE Fougeroux, L Li, AF Sander, AE Sikora Infection and Immunity 91 (12), e00245-23, 2023 | 3 | 2023 |
| Freeze-drying of a capsid virus-like particle-based platform allows stable storage of vaccines at ambient temperature KL Aves, CM Janitzek, CE Fougeroux, TG Theander, AF Sander Pharmaceutics 14 (6), 1301, 2022 | 3 | 2022 |
| Seroprevalence of SARS-CoV-2 antibodies among children and adolescents recruited in a malariometric survey in north-eastern Tanzania July 2021 E Lyimo, C Fougeroux, A Malabeja, J Mbwana, PM Hayuma, E Liheluka, ... BMC Infectious Diseases 22 (1), 846, 2022 | 2 | 2022 |
| Site-Specific O-Glycosylation Analysis of SARS-CoV-2 Spike Protein Produced in Insect and Human Cells. Viruses 2021, 13, 551 I Bagdonaite, AJ Thompson, X Wang, M Søgaard, C Fougeroux, M Frank, ... s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021 | 2 | 2021 |
| Nucleic acid vaccines AFS Bertelsen, MA Nielsen, L Goksøyr, CE Fougeroux, WA De Jongh US Patent App. 18/257,554, 2024 | | 2024 |
| Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), through an innovative virus-like particles (VLP)-based vaccine, enhance the antitumoral activity of a HER-2-VLP … F Ruzzi, L Scalambra, MS Semprini, OM Pittino, C Cappello, S Angelicola, ... European Journal of Cancer 200, 2024 | | 2024 |
